|  |  |  |
| --- | --- | --- |
| **Time-point** | **Anti-NF155 titer** | **subclass** |
| ***Patient 1*** |
| 11/2017 | 1:2,000 | IgG3>>IgG2 |
| 12/2017 | 1:100 | IgG3 |
| 02/2018 | 1:1,000 | IgG3 |
| 03/2018 | 1:100 | IgG3 |
| 05/2018 | 1:200 | IgG3 |
| 07/2018 | 1:200 | IgG3 |
| ***Patient 2*** |
| 07/2014 | 1:1,000 | IgG3 |
| 09/2014 | 1:500 | IgG3 |
| 01/2015 | 1:5,000 | IgG3>>IgG4 |
| 03/2015 | 1:10,000 | IgG3>>IgG4 |
| 04/2015 | 1:5,000 | IgG3>>IgG4 |
| 10/2018 | negative | n/a |

Supplemental Table: Anti-NF155 titers and IgG subclasses of patients 1 and 2 at different time-points. It needs to be noted that both patients were under therapy (including plasma exchange and rituximab).